Isolation and characterization of pseudo degradation products of acalabrutinib using ESI-HRMS/MS and NMR: Formation of possible geometrical isomers

J Pharm Biomed Anal. 2023 Feb 20:225:115214. doi: 10.1016/j.jpba.2022.115214. Epub 2022 Dec 29.

Abstract

A forced degradation study of acalabrutinib (ACB), used to treat relapsed mantle cell lymphoma, was performed to identify and characterize all possible major degradation products formed under different stress conditions. The degradation products (DP) were separated using reverse phase UHPLC system on Kinetex EVO C18 column. Major DPs formed were isolated using semi-preparative HPLC and characterized by LC-ESI-HRMS/MS and NMR. ACB degraded to form seven major degradants (DP-I to DP-VII). DP-I and DP-V were formed under alkaline stress condition, whereas DP-II, DP-III, DP-VI and DP-VII were formed under both acidic and basic conditions. Further, DP-IV was formed when ACB drug was exposed to hydrogen peroxide stress condition. ACB was found to be stable when subjected to aqueous (neutral pH), thermal and UV radiation of 254 nm, as it has not shown any significant degradation under these conditions. Interestingly, two pairs of pseudo geometrical isomeric DPs (DP-II and DP-III, DP-VI and DP-VII) were observed. The plausible degradation pathway of ACB and fragmentation patterns of both ACB and major DPs were discussed.

Keywords: Acalabrutinib; Characterization; Degradation pathways; ESI-HRMS/MS; Forced degradation; Isolation; NMR.

MeSH terms

  • Chromatography, High Pressure Liquid
  • Drug Stability
  • Hydrolysis
  • Magnetic Resonance Spectroscopy
  • Oxidation-Reduction
  • Photolysis
  • Spectrometry, Mass, Electrospray Ionization*
  • Tandem Mass Spectrometry*

Substances

  • acalabrutinib